Please use this identifier to cite or link to this item:
Title: Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Authors: Yuen, HF
Chan, KK
Grills, C
Murray, JT
Platt-Higgins, A
Eldin, OS
O'Byrne, K
Janne, P
Fennell, DA
Johnston, PG
Rudland, PS
El-Tanani, M
First Published: 15-Jan-2012
Citation: CLIN CANCER RES, 2012, 18 (2), pp. 380-391
Abstract: Cancer cells have been shown to be more susceptible to Ran knockdown than normal cells. We now investigate whether Ran is a potential therapeutic target of cancers with frequently found mutations that lead to higher Ras/MEK/ERK [mitogen-activated protein/extracellular signal-regulated kinase (ERK; MEK)] and phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 activities.
DOI Link: 10.1158/1078-0432.CCR-11-2035
ISSN: 1078-0432
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.